Ryvu Therapeutics S.A. reported earnings results for the third quarter and nine months ended September 30, 2023. For the third quarter, the company reported sales was PLN 12.05 million compared to PLN 14.26 million a year ago. Revenue was PLN 16.24 million compared to PLN 19.73 million a year ago. Net loss was PLN 18.25 million compared to PLN 11.8 million a year ago. Basic loss per share from continuing operations was PLN 0.79 compared to PLN 0.64 a year ago. Diluted loss per share from continuing operations was PLN 0.79 compared to PLN 0.64 a year ago.
For the nine months, sales was PLN 35.67 million compared to PLN 14.33 million a year ago. Revenue was PLN 49.59 million compared to PLN 33.82 million a year ago. Net loss was PLN 64.36 million compared to PLN 75.26 million a year ago. Basic loss per share from continuing operations was PLN 2.82 compared to PLN 4.1 a year ago. Diluted loss per share from continuing operations was PLN 2.82 compared to PLN 4.1 a year ago.